Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

22.86 -1.20 (-4.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,286,590
Open 23.55
Bid (Size) 22.40 (100)
Ask (Size) 23.00 (6,600)
Prev. Close 24.06
Today's Range 22.15 - 23.70
52wk Range 14.62 - 26.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program ↗
Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III... 
Via MarketBeat

Performance

YTD
+48.6%
+48.6%
1 Month
+5.1%
+5.1%
3 Month
+29.2%
+29.2%
6 Month
+48.6%
+48.6%
1 Year
+48.6%
+48.6%

More News

Read More
News headline image
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
From Definium Therapeutics, Inc.
Via Business Wire
Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlight ↗
Via Chartmill
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
Via The Motley Fool
News headline image
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium (DFTX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
News headline image
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Via The Motley Fool
Topics Government
News headline image
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium (DFTX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences
From Definium Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Definium Therapeutics, Inc. - Common Shares publicly traded?
Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
What is the current price of Definium Therapeutics, Inc. - Common Shares?
The current price of Definium Therapeutics, Inc. - Common Shares is 22.86
When was Definium Therapeutics, Inc. - Common Shares last traded?
The last trade of Definium Therapeutics, Inc. - Common Shares was at 06/02/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.